142 related articles for article (PubMed ID: 15167523)
1. Preparation of (166)Dy/(166)Ho-EDTMP: a potential in vivo generator system for bone marrow ablation.
Pedraza-López M; Ferro-Flores G; de Murphy CA; Tendilla JI; Villanueva-Sánchez O
Nucl Med Commun; 2004 Jun; 25(6):615-21. PubMed ID: 15167523
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.
Pedraza-López M; Ferro-Flores G; Arteaga de Murphy C; Morales-Ramírez P; Piedras-Ross J; Murphy-Stack E; Hernández-Oviedo O
Nucl Med Biol; 2004 Nov; 31(8):1079-85. PubMed ID: 15607490
[TBL] [Abstract][Full Text] [Related]
3. [166Dy]Dy/166Ho hydroxide macroaggregates: an in vivo generator system for radiation synovectomy.
Ferro-Flores G; Hernández-Oviedo O; Arteaga de Murphy C; Tendilla JI; Monroy-Guzmán F; Pedraza-López M; Aldama-Alvarado K
Appl Radiat Isot; 2004 Dec; 61(6):1227-33. PubMed ID: 15388114
[TBL] [Abstract][Full Text] [Related]
4. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
5. Labeling of biotin with [166Dy]Dy/166Ho as a stable in vivo generator system.
Ferro-Flores G; Arteaga de Murphy C; Pedraza-López M; Monroy-Guzmán F; Meléndez-Alafort L; Tendilla JI; Jiménez-Varela R
Int J Pharm; 2003 Apr; 255(1-2):129-38. PubMed ID: 12672609
[TBL] [Abstract][Full Text] [Related]
6. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.
Chakraborty S; Das T; Banerjee S; Balogh L; Chaudhari PR; Sarma HD; Polyák A; Máthé D; Venkatesh M; Janoki G; Pillai MR
Cancer Biother Radiopharm; 2008 Apr; 23(2):202-13. PubMed ID: 18454689
[TBL] [Abstract][Full Text] [Related]
10. 227Th-EDTMP: a potential therapeutic agent for bone metastasis.
Washiyama K; Amano R; Sasaki J; Kinuya S; Tonami N; Shiokawa Y; Mitsugashira T
Nucl Med Biol; 2004 Oct; 31(7):901-8. PubMed ID: 15464392
[TBL] [Abstract][Full Text] [Related]
11. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H
Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266
[TBL] [Abstract][Full Text] [Related]
12. Preliminary dosimetry of (166)Ho-propylene di-amino tetra (methy1enephosphonicacid) for human based on biodistribution data in rats.
Zolghadri S; Yousefnia H; Jalilian AR; Shiri-Yekta Z; Maragheh MG
J Cancer Res Ther; 2015; 11(4):862-7. PubMed ID: 26881532
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals.
Garnuszek P; Pawlak D; Licińska I; Kamińska A
Appl Radiat Isot; 2003 Apr; 58(4):481-8. PubMed ID: 12672628
[TBL] [Abstract][Full Text] [Related]
14. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation.
Oh SJ; Won KS; Moon DH; Cheon JH; Ha HJ; Jeong JM; Lee HK
Nucl Med Commun; 2002 Jan; 23(1):75-81. PubMed ID: 11748441
[TBL] [Abstract][Full Text] [Related]
15. Radiolanthanide complexes with tetraazamacrocycles bearing methylphosphonate pendant arms as bone seeking agents.
Gano L; Marques F; Campello MP; Balbina M; Lacerda S; Santos I
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):6-15. PubMed ID: 17372568
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of carrier added and no carrier added 90Y-EDTMP as bone seeking therapeutic radiopharmaceutical.
Khalid M; Bokhari TH; Ahmad M; Bhatti HN; Iqbal M; Ghaffar A; Qadir MI
Pak J Pharm Sci; 2014 Jul; 27(4):813-8. PubMed ID: 25015445
[TBL] [Abstract][Full Text] [Related]
17. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
19. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
Yousefnia H; Zolghadri S
Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
[TBL] [Abstract][Full Text] [Related]
20. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
